Last updated: 2026-09-16 10:32:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Invivyd, Inc. (IVVD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.80, with a market capitalisation of $262.87M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.53 to $3.07. This page covers its latest market performance, valuation, price trends and company information.
$262.87M | |
$0.84 | |
$5.20 | |
$0.35 | |
$0.83 | |
41.73K | |
4.27M | |
-- | |
$3.07 | |
$0.53 | |
-- | |
-- |
Invivyd, Inc. (IVVD) is trading at $0.80 in pre-market trading as of 2026-09-16 10:06:00, down 3.25% ($0.03) from the previous close of $0.83
Pre-market trading shows how investors are pricing IVVD before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Invivyd, Inc. (IVVD) moved from $0.83 to $0.80, representing a decline of 2.78% ($0.02).
The stock traded between $0.77 and $0.94 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.90 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10.8%
IVVD is currently trading at $0.80, placing it 10.8% of the way from its 52-week low of $0.53 to its 52-week high of $3.07. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 122 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Invivyd, Inc. (IVVD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.